Abstract Purpose: KRAS G12V is among the most frequent KRAS mutations in non–small cell lung cancer (NSCLC), yet its clinical and molecular features remain poorly understood. Experimental Design: In this retrospective study, we analyzed 636 patients with KRAS G12V–mutated NSCLC...
A Phase 1 clinical trial concluded that setidegrasib targets KRAS G12D mutations effectively, showing promise for lung and pancreatic cancer patients The Florida Cancer Specialists & Research Institute (FCS) has recently participated in a Phase 1 clinical study that sheds...
In the phase 2 ETOP ADEPPT trial, researchers sought to determine whether adagrasib, a KRAS G12C inhibitor, was effective in older patients and those with ECOG PS 2 Adagrasib is effective in older patients with stage IV, KRAS-mutated non-small cell...
Setidegrasib Shows Promise for KRAS G12D-Mutated lung and pancreatic Cancers: NEJM Written By : Dr. Shravani Dali |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2026-04-01T20:15:17+05:30 | Updated On 2 April 2026 12:47 PM IST Setidegrasib, an emerging...
Wungki Park: KRAS G12D Protein Degrader in NSCLC and PDAC Wungki Park, Assistant Attending at Memorial Sloan Kettering Cancer Center and Assistant Professor of Medicine at Weill Cornell Medicine shared a post on LinkedIn. “We are entering a new phase...
Wungki Park: KRAS G12D Protein Degrader in NSCLC and PDAC / Aditya Shetty, Alexander I. Spira, Anthony W. Tolcher, Antoine Hollebecque, Antoine Italiano, Anup Wungki Park/LinkedIn Wungki Park: KRAS G12D Protein Degrader in NSCLC and PDAC Wungki Park, Assistant Attending...
Adagrasib, a second-generation KRAS G12C inhibitor, has demonstrated a 31% confirmed objective response rate (cORR) in elderly patients with an ECOG performance status (PS) of 0 or 1. However, updated results from the ETOP ADEPPT trial (NCT05673187) reveal that patients...
Early activity and tolerability were observed among patients who received setidegrasib, an investigational KRAS G12D-targeted protein degrader, for non–small cell lung cancer (NSCLC) harboring KRAS G12D mutations, according to data from a phase 1 trial presented at the 2026 European...
